MacroGenics (MGNX) : Average target price received by MacroGenics (MGNX) is $42.4 with an expected standard deviation of $11.15. The most aggressive target on the stock is $52, whereas the most downbeat target is $26. 5 financial analysts are currently covering the stock.
MacroGenics (MGNX) : 4 brokerage houses believe that MacroGenics (MGNX) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on MacroGenics (MGNX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.4.
Also, Equity Analysts at the Brokerage Firm, Citigroup, maintains their rating on the shares of MacroGenics (NASDAQ:MGNX). Citigroup has a Neutral rating on the shares. As per the latest research report, the brokerage house raises the price target to $32 per share from a prior target of $27. The rating by the firm was issued on August 5, 2016.
MacroGenics (NASDAQ:MGNX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $29.83 and $29.70 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $30.05, notching a gain of 0.81% for the day. The total traded volume was 215,721 . The stock had closed at $29.81 on the previous day.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. The Company has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.